iosBio employs a sophisticated, biology-led Artificial Intelligence approach to vaccine design. We leverage computational power and proprietary design for “in silico” screening and optimization of antigen candidates. This allows us to rapidly identify unique structural features and modifications that enhance immunogenicity, stability, and manufacturability, significantly accelerating the development timeline compared to traditional methods.

This AI-assisted approach was critical in developing our patented antigens for the OraPro-EBV vaccine. By modelling and refining key EBV proteins (gp350, gHgL, gB), we engineered enhanced versions designed to elicit class-leading neutralising antibody responses and provide comprehensive protection against viral entry mechanisms.